These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Prognostic value of primary tumor volume after concurrent chemoradiation with daily low-dose cisplatin for advanced-stage head and neck carcinoma. Hoebers FJ, Pameijer FA, de Bois J, Heemsbergen W, Balm AJ, Schornagel JH, Rasch CR. Head Neck; 2008 Sep; 30(9):1216-23. PubMed ID: 18642295 [Abstract] [Full Text] [Related]
26. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus cisplatin monotherapy. Urba S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, Peterson P, Cohen EE. Oral Oncol; 2012 Aug; 48(8):723-9. PubMed ID: 22414289 [Abstract] [Full Text] [Related]
29. Radiotherapy with or without erythropoietin for anemic patients with head and neck cancer: a randomized trial of the Radiation Therapy Oncology Group (RTOG 99-03). Machtay M, Pajak TF, Suntharalingam M, Shenouda G, Hershock D, Stripp DC, Cmelak AJ, Schulsinger A, Fu KK, Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1008-17. PubMed ID: 17716826 [Abstract] [Full Text] [Related]
30. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Cancer; 2008 Feb 01; 112(3):535-43. PubMed ID: 18076014 [Abstract] [Full Text] [Related]
34. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck. McCloskey SA, Jaggernauth W, Rigual NR, Hicks WL, Popat SR, Sullivan M, Mashtare TL, Khan MK, Loree TR, Singh AK. Am J Clin Oncol; 2009 Dec 01; 32(6):587-91. PubMed ID: 19581794 [Abstract] [Full Text] [Related]
35. IMRT reirradiation of head and neck cancer-disease control and morbidity outcomes. Sulman EP, Schwartz DL, Le TT, Ang KK, Morrison WH, Rosenthal DI, Ahamad A, Kies M, Glisson B, Weber R, Garden AS. Int J Radiat Oncol Biol Phys; 2009 Feb 01; 73(2):399-409. PubMed ID: 18556144 [Abstract] [Full Text] [Related]
36. Promoter methylation of TIMP3 and CDH1 predicts better outcome in head and neck squamous cell carcinoma treated by radiotherapy only. De Schutter H, Geeraerts H, Verbeken E, Nuyts S. Oncol Rep; 2009 Feb 01; 21(2):507-13. PubMed ID: 19148529 [Abstract] [Full Text] [Related]
38. Internal consistency of the traditional Chinese character version of the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N). Chang JT, Chang CH, Juang YY, Hsiao JC, Lin CY, Huang SF, Huang YC, Kuan KH, Liao CT, Wang HM, Chen IH. Chang Gung Med J; 2008 Feb 01; 31(4):384-94. PubMed ID: 18935797 [Abstract] [Full Text] [Related]